298197-04-3

298197-04-3 structure

Name: Fatostatin
Chemical Name: fatostatin
CAS Number: 298197-04-3
Molecular Formula: C₁₈H₁₉BrN₂S
Molecular Weight: 375.326
Catalog: Signaling Pathways Metabolic Enzyme/Protease Fatty Acid Synthase (FAS)
Create Date: 2016-07-06 14:25:40
Modify Date: 2024-01-10 07:21:07
Fatostatin hydrobromide (125B11 hydrobromide), a specific inhibitor of SREBP activation, impairs the activation of SREBP-1 and SREBP-2. Fatostatin hydrobromide binds to SCAP (SREBP cleavage-activating protein), and inhibits the ER-Golgi translocation of SREBPs. Fatostatin hydrobromide decreases the transcription of lipogenic genes in cells. Fatostatin hydrobromide possesses antitumor properties, and lowers hyperglycemia in ob/ob mice[1][2].

Name	fatostatin
Synonyms	2-(2-propylpyridin-4-yl)-4-p-tolylthiazole hydrobromide FATOSTATIN A Fatostatin (hydrobromide) 4-[4-(4-Methylphenyl)-1,3-thiazol-2-yl]-2-propylpyridine hydrobromide (1:1) Pyridine, 4-[4-(4-methylphenyl)-2-thiazolyl]-2-propyl-, hydrobromide (1:1) FATOSTATIN (2-(2-PROPYLPYRIDIN-4-YL)-4-(P-TOLYL)THIAZOLE) Fatostatin A Hydrobromide

Description	Fatostatin hydrobromide (125B11 hydrobromide), a specific inhibitor of SREBP activation, impairs the activation of SREBP-1 and SREBP-2. Fatostatin hydrobromide binds to SCAP (SREBP cleavage-activating protein), and inhibits the ER-Golgi translocation of SREBPs. Fatostatin hydrobromide decreases the transcription of lipogenic genes in cells. Fatostatin hydrobromide possesses antitumor properties, and lowers hyperglycemia in ob/ob mice[1][2].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Metabolic Enzyme/Protease >> Fatty Acid Synthase (FAS)
In Vitro	Fatostatin hydrobromide (125B11 hydrobromide) (0.1-1 μM; 3 days) inhibits the androgen-independent prostate cancer cell proliferation (IC50=0.1 μM) in an independent of the known IGF1-signaling pathway. Fatostatin hydrobromide inhibits insulin-induced adipogenesis of 3T3-L1 cells[1]. Cell Proliferation Assay[1] Cell Line: DU-145 cells Concentration: 0.1, 1 μM Incubation Time: 3 days Result: Impaired the IGF1-induced growth at an IC50 of 0.1 μM.
In Vivo	Fatostatin hydrobromide (125B11 hydrobromide) (30 mg/kg; 150 mL; i.p.; daily for 28 days) reduces adiposity, ameliorates fatty liver by reducing triglyceride (TG) storage, and lowers hyperglycemia in ob/ob mice[2]. Animal Model: Four-to-five-week-old homozygous male obese (ob/ob) mice (C57BL/6J)[2] Dosage: 30 mg/kg; 150 mL Administration: i.p. injection; daily for 28 days Result: Blocked increases in body weight, blood glucose, and hepatic fat accumulation in obese ob/ob mice, even under uncontrolled food intake.
References	[1]. Choi Y, et al. Identification of bioactive molecules by adipogenesis profiling of organic compounds. J Biol Chem. 2003 Feb 28;278(9):7320-4. [2]. Kamisuki S, et al. A small molecule that blocks fat synthesis by inhibiting the activation of SREBP. Chem Biol. 2009 Aug 28;16(8):882-92.

Molecular Formula	C₁₈H₁₉BrN₂S
Molecular Weight	375.326
Exact Mass	374.045227
PSA	54.02000
LogP	6.09110
Storage condition	-20℃

Symbol	GHS07
Signal Word	Warning
Hazard Statements	H302
RIDADR	NONH for all modes of transport